Targeting Innate Immunity in Glioma Therapy

Andrew G. Gillard,Dong Ho Shin,Lethan A. Hampton,Andres Lopez-Rivas,Akhila Parthasarathy,Juan Fueyo,Candelaria Gomez-Manzano
DOI: https://doi.org/10.3390/ijms25020947
IF: 5.6
2024-01-12
International Journal of Molecular Sciences
Abstract:Currently, there is a lack of effective therapies for the majority of glioblastomas (GBMs), the most common and malignant primary brain tumor. While immunotherapies have shown promise in treating various types of cancers, they have had limited success in improving the overall survival of GBM patients. Therefore, advancing GBM treatment requires a deeper understanding of the molecular and cellular mechanisms that cause resistance to immunotherapy. Further insights into the innate immune response are crucial for developing more potent treatments for brain tumors. Our review provides a brief overview of innate immunity. In addition, we provide a discussion of current therapies aimed at boosting the innate immunity in gliomas. These approaches encompass strategies to activate Toll-like receptors, induce stress responses, enhance the innate immune response, leverage interferon type-I therapy, therapeutic antibodies, immune checkpoint antibodies, natural killer (NK) cells, and oncolytic virotherapy, and manipulate the microbiome. Both preclinical and clinical studies indicate that a better understanding of the mechanisms governing the innate immune response in GBM could enhance immunotherapy and reinforce the effects of chemotherapy and radiotherapy. Consequently, a more comprehensive understanding of the innate immune response against cancer should lead to better prognoses and increased overall survival for GBM patients.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the current poor treatment effect of glioblastoma (GBM). GBM is the most common and most aggressive primary brain tumor. The current standard treatment methods have not changed significantly since 2005 and mainly include surgical resection, radiotherapy, and chemotherapy (such as temozolomide). However, these treatment methods have limited improvement on the overall survival rate of patients, with a median survival period of only about 15 months and a 5 - year survival rate of about 36%. The paper points out that although immunotherapy has shown certain potential in treating other types of cancers, it has limited effect in improving the overall survival rate of GBM patients. This is mainly because the tumor micro - environment of GBM is considered "immune - cold", lacking tumor - infiltrating T cells, resulting in poor efficacy of immunotherapy. In addition, GBM can support its growth by regulating and using normal brain cells, affect all cell types in the tumor micro - environment, and inhibit the responses of innate and adaptive immune cells. Therefore, in order to improve the treatment effect of GBM, a deeper understanding of the molecular and cellular mechanisms leading to immunotherapy resistance, especially the mechanisms of the innate immune response, is required. By reviewing the current treatment methods aiming at enhancing the innate immune response, the paper explores how to improve the treatment effect of GBM through strategies such as activating Toll - like receptors, inducing stress responses, enhancing the innate immune response, using type I interferon therapy, therapeutic antibodies, immune checkpoint antibodies, natural killer (NK) cells, oncolytic virus therapy, and manipulating the microbiome. Overall, the paper aims to provide a theoretical basis for the development of more effective treatment strategies by in - depth study of the role of the innate immune system in GBM treatment, thereby improving the survival rate and prognosis of patients.